Literature DB >> 12779111

Pharmacokinetics of oral tramadol drops for postoperative pain relief in children aged 4 to 7 years--a pilot study.

K A Payne1, J A Roelofse, E A Shipton.   

Abstract

Tramadol hydrochloride is an analgesic with mu receptor activity suitable for administration to children as oral drops. As the serum concentration profile and pharmacokinetic parameters in young children are not known via this route, we studied 24 healthy ASA 1 children to determine those parameters. The children's mean age was 5.3 +/- 1.1 years and their mean weight was 17.8 +/- 3.1 kg. They underwent general anesthesia with sevoflurane for dental surgery. The mean duration of anesthesia was 27.9 +/- 10.1 minutes. Tramadol 1.5 mg/kg (this dose was chosen because we have previously shown it to be effective in providing analgesia following pediatric dental surgery) was administered as oral drops 30 minutes before anesthesia. Venous blood samples were taken following the tramadol at 30-minute intervals for 4 hours, every 2 hours for 6 hours, and every 4 hours for 12 hours. The samples were centrifuged and the serum stored at -20 degrees C, and nonstereoselective gas chromatography was used to determine the concentration of (+) and (-) tramadol enantiomers plus their o-demethyltramadol (M1) metabolite concentrations. The tramadol absorption was rapid, the maximum measured serum concentration present occurring before the first sample at 30 minutes. That first sample had a concentration of 352 +/- 83.4 ng/mL. The concentration remained above the 100 ng/mL analgesic level until 6.8 +/- 0.9 hours. The elimination half-life was 3.6 +/- 1.1 hours, the serum clearance 5.6 +/- 2.7 mL/kg/min, and the volume of distribution 4.1 +/- 1.2 L/kg. The (+) enantiomer concentration was 14.2 +/- 4.9% greater than that of the (-) enantiomer. The M1 metabolites had a (-) enantiomer concentration 92.3 +/- 75.1% greater than the (+) enantiomer. From the peak concentration at 4.5 +/- 1.5 hours, the concentration of the metabolite was approximately one third that of the parent drug. The M1 elimination half-life was 5.8 +/- 1.7 hours. Apart from the rapid rise in the serum concentration, these kinetic parameters are similar to those seen in healthy young adults. The concentration profile supports an effective clinical duration in the region of 7 hours.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12779111      PMCID: PMC2007413     

Source DB:  PubMed          Journal:  Anesth Prog        ISSN: 0003-3006


  11 in total

1.  Oral tramadol: analgesic efficacy in children following multiple dental extractions.

Authors:  J A Roelofse; K A Payne
Journal:  Eur J Anaesthesiol       Date:  1999-07       Impact factor: 4.330

2.  Pharmacokinetics of tramadol in children after i.v. or caudal epidural administration.

Authors:  B V Murthy; K S Pandya; P D Booker; A Murray; W Lintz; R Terlinden
Journal:  Br J Anaesth       Date:  2000-03       Impact factor: 9.166

3.  Determination of tramadol in various dosage forms by capillary isotachophoresis.

Authors:  M Pospísilová; M Polásek; V Jokl
Journal:  J Pharm Biomed Anal       Date:  1998-12       Impact factor: 3.935

4.  Preoperative parental anxiety predicts behavioural and emotional responses to induction of anaesthesia in children.

Authors:  J C Bevan; C Johnston; M J Haig; G Tousignant; S Lucy; V Kirnon; I K Assimes; R Carranza
Journal:  Can J Anaesth       Date:  1990-03       Impact factor: 5.063

Review 5.  [Pharmacology of tramadol].

Authors:  P Dayer; J Desmeules; L Collart
Journal:  Drugs       Date:  1997       Impact factor: 9.546

Review 6.  Pharmacological models and their use in clinical anaesthesia.

Authors:  H Schwilden; H Stoeckel; J Schüttler; P M Lauven
Journal:  Eur J Anaesthesiol       Date:  1986-05       Impact factor: 4.330

7.  [Biotransformation of tramadol in man and animal (author's transl)].

Authors:  W Lintz; S Erlaçin; E Frankus; H Uragg
Journal:  Arzneimittelforschung       Date:  1981

8.  Effects of the central analgesic tramadol on the uptake and release of noradrenaline and dopamine in vitro.

Authors:  B Driessen; W Reimann; H Giertz
Journal:  Br J Pharmacol       Date:  1993-03       Impact factor: 8.739

9.  Bioavailability of enteral tramadol formulations. 1st communication: capsules.

Authors:  W Lintz; H Barth; G Osterloh; E Schmidt-Böthelt
Journal:  Arzneimittelforschung       Date:  1986-08

10.  Pharmacokinetics of tramadol and bioavailability of enteral tramadol formulations. 2nd communication: drops with ethanol.

Authors:  W Lintz; H Barth; R Becker; E Frankus; E Schmidt-Böthelt
Journal:  Arzneimittelforschung       Date:  1998-05
View more
  5 in total

1.  PharmGKB summary: tramadol pathway.

Authors:  Li Gong; Ulrike M Stamer; Mladen V Tzvetkov; Russ B Altman; Teri E Klein
Journal:  Pharmacogenet Genomics       Date:  2014-07       Impact factor: 2.089

Review 2.  Guidelines on paediatric dosing on the basis of developmental physiology and pharmacokinetic considerations.

Authors:  Imke H Bartelink; Carin M A Rademaker; Alfred F A M Schobben; John N van den Anker
Journal:  Clin Pharmacokinet       Date:  2006       Impact factor: 6.447

Review 3.  Tramadol for postoperative pain treatment in children.

Authors:  Alexander Schnabel; Sylvia U Reichl; Christine Meyer-Frießem; Peter K Zahn; Esther Pogatzki-Zahn
Journal:  Cochrane Database Syst Rev       Date:  2015-03-18

Review 4.  Pediatric palliative care: use of opioids for the management of pain.

Authors:  Boris Zernikow; Erik Michel; Finella Craig; Brian J Anderson
Journal:  Paediatr Drugs       Date:  2009       Impact factor: 3.022

Review 5.  When the Safe Alternative Is Not That Safe: Tramadol Prescribing in Children.

Authors:  Frédérique Rodieux; Laszlo Vutskits; Klara M Posfay-Barbe; Walid Habre; Valérie Piguet; Jules A Desmeules; Caroline F Samer
Journal:  Front Pharmacol       Date:  2018-03-05       Impact factor: 5.810

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.